Microbiome Influencers of Checkpoint Blockade-Associated Toxicity

Authors

Yinghong Wang
Robert R Jenq
Jennifer A Wargo
Stephanie S Watowich

Publication Date

3-6-2023

Journal

Journal of Experimental Medicine

Abstract

Immunotherapy has greatly improved cancer outcomes, yet variability in response and off-target tissue damage can occur with these treatments, including immune checkpoint inhibitors (ICIs). Multiple lines of evidence indicate the host microbiome influences ICI response and risk of immune-related adverse events (irAEs). As the microbiome is modifiable, these advances indicate the potential to manipulate microbiome components to increase ICI success. We discuss microbiome features associated with ICI response, with focus on bacterial taxa and potential immune mechanisms involved in irAEs, and the overall goal of driving novel approaches to manipulate the microbiome to improve ICI efficacy while avoiding irAE risk.

Keywords

Humans, Antineoplastic Agents, Immunological, Neoplasms, Microbiota, Immunotherapy, Retrospective Studies

Comments

PMID: 36622383

DOI

10.1084/jem.20220948

PMID

36622383

PMCID

PMC9836236

PubMedCentral® Posted Date

January 2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes